1. Home
  2. ADNT vs ARDX Comparison

ADNT vs ARDX Comparison

Compare ADNT & ARDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Adient plc

ADNT

Adient plc

HOLD

Current Price

$19.76

Market Cap

1.7B

ML Signal

HOLD

Logo Ardelyx Inc.

ARDX

Ardelyx Inc.

HOLD

Current Price

$5.78

Market Cap

1.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ADNT
ARDX
Founded
2016
2007
Country
Ireland
United States
Employees
N/A
N/A
Industry
Auto Parts:O.E.M.
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.7B
1.6B
IPO Year
2016
2014

Fundamental Metrics

Financial Performance
Metric
ADNT
ARDX
Price
$19.76
$5.78
Analyst Decision
Hold
Strong Buy
Analyst Count
10
7
Target Price
$24.85
$15.14
AVG Volume (30 Days)
716.9K
3.6M
Earning Date
05-05-2026
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$17,439,000,000.00
$2,607,000.00
Revenue This Year
$2.76
$38.22
Revenue Next Year
$2.47
$33.85
P/E Ratio
N/A
N/A
Revenue Growth
7.56
N/A
52 Week Low
$10.04
$3.50
52 Week High
$27.32
$8.40

Technical Indicators

Market Signals
Indicator
ADNT
ARDX
Relative Strength Index (RSI) 28.00 36.90
Support Level $18.47 $5.49
Resistance Level $19.93 $6.23
Average True Range (ATR) 0.81 0.31
MACD -0.53 -0.06
Stochastic Oscillator 1.94 13.56

Price Performance

Historical Comparison
ADNT
ARDX

About ADNT Adient plc

Adient began trading Oct. 31, 2016, when Johnson Controls spun off its automotive experience segment. Adient is a leading seating supplier to the industry with about a midteens share of the global market including unconsolidated joint venture business. Its share in China is around 20%, down from about 45%, following the sale of its main joint venture there at the end of fiscal 2021. Unconsolidated revenue from joint ventures was about $3.5 billion in fiscal 2025 and consolidated China revenue was $1.3 billion. The company is headquartered in Ireland but has corporate offices in the Detroit area. Fiscal 2025 (Sept. 30 year-end) consolidated revenue, which excludes joint venture sales, was $14.5 billion.

About ARDX Ardelyx Inc.

Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. It product Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.

Share on Social Networks: